Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
Evaluation of the decrease of the secretion of saliva in patients with amyotrophic lateral
sclerosis by a local ultrasound-guided bilateral injection of botulinum toxin type A in
parotids and submandibular glands. The investigators want to demonstrate 1 month after the
injection, by a multicenter French randomized double blind study, an improvement of at least
25 % of the functional embarrassment due to saliva, estimated with a visual analogue scale, a
decrease of the quantity of saliva and a decrease of the embarrassment for the main
caregiver.
Phase:
Phase 2
Details
Lead Sponsor:
Hospices Civils de Lyon
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA